Clinical trials: Brain Neoplasms, open to volunteers
Adult Glioblastoma, High Grade Glioma
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or…
- Conditions
- Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
- Trial name
- PNOC020 (NCT04573140)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Florida
Recurrent Oligodendroglioma, Progressive Oligodendroglioma
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive…
- Trial name
- ADAGiO (NCT06254326)
- Testing
- TTRNA-DC vaccines with GM-CSF, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
High-grade Glioma, Diffuse Intrinsic Pontine Glioma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in newly diagnosed and recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse…
- Trial name
- Peds IMPACT (NCT06946680)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Small Cell Lung Cancer ( SCLC ), Brain Injury
Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury
The study aims to enroll the small cell lung cancer(SCLC) who meet the indications for prophylactic cranial irradiation (PCI): patients with limited-stage SCLC who have achieved complete or partial remission after first-line…
- Trial name
- NCT07905937
- Testing
- PD-1 Inhibitor + Chemotherapy+PCI, chemotherapy+PCI
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guizhou Medical University
Neurologic Disorders
Evaluation and Treatment of Neurosurgical Disorders
Objective: This protocol is designed to allow the Surgical Neurology Branch to evaluate and treat the neurosurgical disorders of protocol participants.
- Trial name
- NCT00060541
- Testing
- Laboratory tests, Radiological exams
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Brain Metastases
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases.
- Trial name
- NCT06072807
- Testing
- Brain Imaging with 18F-FES
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Brain Metastases, Bone Metastases
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance…
- Conditions
- Brain Metastases, Bone Metastases, Head and Neck Cancer, Lung Cancer
- Trial name
- DART (NCT07185958)
- Testing
- Dual-energy CT (DECT), Iodine-based contrast agent, Magnetic Resonance Imaging (MRI)
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Aalborg University Hospital
Brain Tumor Adult, Brain Metastases From Solid Tumors
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors.
- Conditions
- Brain Tumor Adult, Brain Metastases From Solid Tumors, Brain Tumor, Primary, Brain Tumor
- Trial name
- NCT07226466
- Testing
- Blood sample, Brain magnetic resonance imaging (MRI), Brain Health Assessment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Brain Tumors, Transcranial Magnetic Stimulation
rTMS for Postoperative Brain Tumor Patients
When doctors perform surgery to remove brain tumors, the goal is to take out as much of the tumor as possible while keeping the patient's brain functions intact.
- Conditions
- Brain Tumors, Transcranial Magnetic Stimulation, Motor Deficit, Quality of Life
- Trial name
- NCT07530536
- Testing
- Transcranial magnetic stimulation (TMS)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Brian J.Gill
Brain Neoplasms, Sleep Initiation and Maintenance Disorders
Lemborexant on Perioperative Sleep Quality in Patients With Brain Tumor Undergoing Surgery
This study tests whether lemborexant can improve perioperative sleep quality in people with brain tumor undergoing surgery. Adults with brain tumor scheduled for surgery may join.
- Trial name
- NCT07903051
- Testing
- Lemborexant 5 mg
- Volunteers
- 112 people
- Sponsor
- Beijing Tiantan Hospital
Carcinoma, Non-Small-Cell Lung
Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
Non-small cell lung cancer frequently spreads to the brain, and brain metastases are associated with poor prognosis and limited treatment response.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Neoplasm Metastasis
- Trial name
- SIREC-Poumon (NCT07904013)
- Testing
- Radiomic analysis; Bulk RNA sequencing
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Cardiotoxicity, HER2/Neu Positive
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment.
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma
- Trial name
- NCT03418961
- Testing
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Where
- 590 sites in United States, Puerto Rico and 2 more
- Volunteers
- 491 people
- Sponsor
- SWOG Cancer Research Network
Primary Brain Neoplasm
An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial
This clinical trial evaluates the effects of a partnered exercise program, called Exercise Together, on participants with primary brain tumors and their caregivers.
- Trial name
- NCT07278440
- Testing
- Electronic Health Record Review, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Recurrent Glioblastoma
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous…
- Trial name
- NCT07297212
- Testing
- Pumitamig, Bevacizumab, Temozolomide
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
Small Cell Lung Cancer, Brain Metastases, Adult
Tarlatamab for SCLC Brain Metastases
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
- Trial name
- T-BRAIN (NCT07402343)
- Testing
- Tarlatamab
- Where
- 4 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- Maastricht University Medical Center
Meningioma
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
- Trial name
- STELLAR-201 (NCT07428616)
- Testing
- Zanzalintinib
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Exelixis
Diffuse Intrinsic Pontine Glioma, DIPG
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG).
- Conditions
- Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor
- Trial name
- NCT07680439
- Testing
- BCB-276
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- BrainChild Bio, Inc
Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in…
- Trial name
- OPAL (NCT07739017)
- Testing
- CT-179
- Where
- 6 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Olivia Newton-John Cancer Research Institute